Our pooled estimate (RR: 0.72) aligns closely with Zelniker et al.’s Lancet 2019 meta-analysis [14] (RR: 0.69, 95% CI: 0.61-0.79) and some other significant studies [15] supporting SGLT2 inhibitors as a cornerstone therapy in HF prevention among T2DM patients. Here, SLC5A2 is linked to type 2 diabetes mellitus.